Compare Cytokinetics Inc (CYTK) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Omnicom Group Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Omnicom Group Inc. trades at $81.48 (market cap $23.01B). The key difference: Omnicom Group Inc. is far larger — about 2.1× Cytokinetics Inc's market cap, and Omnicom Group Inc. pays a 3.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | OMC | |
|---|---|---|
Market Cap | $11.12B | $23.01B |
Sector | Technology | Media |
52-Week High | $87.26 | $85.80 |
52-Week Low | $33.23 | $67.27 |
Enterprise Value | $11.59B | $30.24B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Omnicom Group (OMC) trades at $82.55, up 0.76% today, with a bullish technical signal from moving averages. The stock shows mixed earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results due July 28, 2026. Revenue grew to $17.27B in 2025, though net income was negative, and cash flow improved significantly. Recent news highlights partnerships with IBM, Netflix, and NBCUniversal, enhancing its media and advertising solutions.
Outlook is cautiously optimistic with a consensus price target of $105.75, implying 28% upside, but risks include intense competition and thin profit margins. The stock offers value with a P/E of 12.16 and a dividend, yet investors should monitor earnings sustainability and debt levels amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
